| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
AML Panel by FISH : 1001103
Test CodeMDFCPCAMLP or 1001103
Alias/See Also
acute myelogenous leukemia panel
CPT Codes
88271x10, 88275x5
Includes
Panel includes: ETO-AML1, t(8;21)/BCR-ABL1 translocation, t(9;22)/PML-RARA, t(15;17)/CBFB-MYH11 translocation, inv(16), t(16;16)/MLL gene rearrangement (11q23).
Instructions
Bone Marrow aspirate in a green top sodium heparin tube (2-3 mL) or Peripheral Blood in a green top sodium heparin tube (2-10 mL).
Transport Container
Blood or Bone Marrow: Do not centrifuge.
Transport Temperature
Blood or Bone Marrow: Ambient temperature within 24 hours. Specimen can be refrigerated if not transported immediately. Do not freeze. Protect from heat with a cold pack.
Specimen Stability
Blood and Bone Marrow: Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable
Methodology
Fluorescence in situ hybridization (FISH)
Setup Schedule
Sunday - Saturday
Report Available
Up to 7 days
1-2 days for new diagnosis
1-2 days for new diagnosis
Limitations
Laboratory test results should always be considered in the context of clinical observations. This test was developed and its performance characteristics determined by med fusion. It has not been cleared or approved by the U.S. Food and Drug Administration
(FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments
of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.
(FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments
of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.
Reference Range
An interpretive report will be provided.
Clinical Significance
Acute Myeloid Leukemia (AML) is classified into several subtypes based on recurrent chromosomal translocations and inversions. The most common are balanced chromosome abnormalities t(8;21)(q22;q22), inv(16)(p13.1q22) or t(16;16)(p13.1;q22), t(15;17)(q22;q12) and t(9;11)(p22;q23). Each of these structural chromosome rearrangements creates a fusion gene encoding a chimeric protein which aids in leukemogenesis.
Performing Laboratory
med fusion
